top of page
  • Recruiting
    • Dec 31, 2018

NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM

Updated: Sep 24, 2022

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Personalized Vaccine Myeloma

This early phase I trial studies the side effects of personalized vaccine in treating participants with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.


Sponsor

M.D. Anderson Cancer Center

 

ClinicalTrials.gov Identifier: NCT03631043

Official Title: A Personalized Vaccine for the Immune Prevention of Multiple Myeloma

First Posted : August 15, 2018

Click here for details on ClinicalTrials.gov

 

Procedure: Biopsy Specimen Radiography

Drug: Lenalidomide